Monitoring soluble cMET and ctDNA in metastatic uveal melanoma patients to track early disease progression on immunotherapies
Abstract Background Metastatic uveal melanoma (mUM) is a rare malignancy and is different from metastatic cutaneous melanoma (mCM) in tumor characteristics and efficacy to immunotherapies. Tumor-specific biomarkers are required for mUM patients to monitor early disease progression on immunotherapies...
Saved in:
| Main Authors: | Devayani Machiraju, Christian H Ziener, Elena Clementi, Francisco García-Asencio, Jennifer Hüllein, Jasmin Richter, Bénédicte Lenoir, Melanie Wiecken, Daniel Hübschmann, Dirk Jäger, Jessica C Hassel |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-07-01
|
| Series: | Journal of Experimental & Clinical Cancer Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13046-025-03451-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy and Tolerability of Tebentafusp in Metastatic Uveal Melanoma: A Real-life Retrospective Multicentre Study
by: Lucille Vitek, et al.
Published: (2024-12-01) -
Efficacy and safety of tebentafusp in patients with metastatic uveal melanoma: A systematic review and meta-analysis
by: Yating Dian, et al.
Published: (2024-12-01) -
ANALYSIS OF METASTASES AND SURVIVAL RATES IN PATIENTS WITH UVEAL MELANOMA
by: S. V. Saakyan, et al.
Published: (2015-04-01) -
Combined stereotactic radiation therapy and immunotherapy for metastatic uveal melanoma
by: Valeria V. Nazarova, et al.
Published: (2025-05-01) -
Revealing the structural microenvironment of high metastatic risk uveal melanomas following decellularisation
by: Karen Aughton, et al.
Published: (2024-11-01)